pISSN 1226-6051
eISSN 2508-786X

Table. 1.

Table. 1.

Baseline characteristics of the study population: everolimus with low dose tacrolimus group and conventional dose tacrolimus group

Characteristics EVR+Low TAC (N=40) TAC (N=78) p-value
Sex, male, n (%) 34 (85.0) 54 (69.2) 0.063
Age, mean±SD 51.7±9.4 53.7±8.4 0.245
Height, cm, mean±SD 167.5±8.3 165.1±8.7 0.152
Weight, kg, mean±SD 67.9±11.8 65.8±10.5 0.329
BMI, kg/m2, mean±SD 24.1±3.5 24.1±3.4 0.994
Type of LT, n (%) 0.864
LDLT 25 (62.5) 50 (64.1)
DDLT 15 (37.5) 28 (35.9)
Indication for LT, n (%) 0.768
Hepatitis B 20 (50.0) 42 (53.8)
Hepatocellular carcinoma 21 (52.5) 37 (47.4)
Alcoholic liver cirrhosis 10 (25.0) 18 (23.1)
Wilson’s disease 1 (2.5) 3 (3.8)
Hepatitis C 1 (2.5) 4 (5.1)
Others** 8 (20.0) 6 (7.7)
MELD score, mean±SD 18.7±14.0 18.6±10.3 0.970
Comorbidities, n (%)
Hypertension 10 (25.0) 19 (24.4) 0.939
Diabetes mellitus 14 (35.0) 21 (26.9) 0.363
Dyslipidemia 2 (5.0) 1 (1.3) 0.265
Renal function, mean±SD
Creatinine, mg/dL 1.4±0.8 1.1±0.5 0.013*
eGFR, mL/min/1.73 m2 69.4±34.9 77.6±31.3 0.199

EVR+Low TAC: everolimus+low dose tacrolimus cohort

TAC: conventional dose tacrolimus cohort

SD: standard deviation

LT: liver transplantation

LDLT: living donor liver transplantation

DDLT: deceased donor liver transplantation

MELD: model for end-stage liver disease

*
p<0.05

** Others: autoimmune hepatitis, fulminant hepatitis, primary biliary cirrhosis, toxic liver disease, hepatitis E

eGFR by MDRD: estimated glomerular filtrated-modification of diet in renal disease

Korean J Clin Pharm 2021;31:44-52 https://doi.org/10.24304/kjcp.2021.31.1.44
© 2021 Korean J Clin Pharm